US3696189A
(en)
*
|
1970-05-18 |
1972-10-03 |
Frank M Snyder |
Stabilized antibiotic and method
|
US3938515A
(en)
*
|
1971-12-20 |
1976-02-17 |
Alza Corporation |
Novel drug permeable wall
|
US4091091A
(en)
*
|
1973-11-08 |
1978-05-23 |
Eli Lilly And Company |
Stabilized nitroglycerin tablets
|
US3939259A
(en)
*
|
1974-05-24 |
1976-02-17 |
Anthony Pescetti |
Coating composition and therapeutic preparation incorporating same
|
AU520409B2
(en)
*
|
1977-05-25 |
1982-01-28 |
Commonwealth Scientific And Industrial Research Organisation |
Controlled release composition
|
DD146547A5
(de)
*
|
1978-07-15 |
1981-02-18 |
Boehringer Sohn Ingelheim |
Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
|
SE426548B
(sv)
*
|
1978-12-05 |
1983-01-31 |
Haessle Ab |
Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
|
SE7813246L
(sv)
*
|
1978-12-22 |
1980-06-23 |
Haessle Ab |
Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
|
IE48715B1
(en)
*
|
1978-12-22 |
1985-05-01 |
Elan Corp Plc |
New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
|
US4308251A
(en)
*
|
1980-01-11 |
1981-12-29 |
Boots Pharmaceuticals, Inc. |
Controlled release formulations of orally-active medicaments
|
DE3000979A1
(de)
*
|
1980-01-12 |
1981-07-23 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
|
US4547358A
(en)
*
|
1980-05-06 |
1985-10-15 |
Mead Johnson & Company |
Sustained release tablet containing at least 95 percent theophylline
|
US4465660A
(en)
*
|
1981-04-01 |
1984-08-14 |
Mead Johnson & Company |
Sustained release tablet containing at least 95 percent theophylline
|
DE3126703A1
(de)
|
1981-07-07 |
1983-01-27 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Bromhexin-retardform und verfahren zu ihrer herstellung
|
DE3278491D1
(en)
*
|
1981-07-15 |
1988-06-23 |
Key Pharma |
Sustained release theophyline
|
US4587118A
(en)
*
|
1981-07-15 |
1986-05-06 |
Key Pharmaceuticals, Inc. |
Dry sustained release theophylline oral formulation
|
DE3381877D1
(de)
*
|
1982-03-16 |
1990-10-18 |
Univ Rockefeller |
Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
|
US4421736A
(en)
*
|
1982-05-20 |
1983-12-20 |
Merrel Dow Pharmaceuticals Inc. |
Sustained release diethylpropion compositions
|
US4415547A
(en)
*
|
1982-06-14 |
1983-11-15 |
Sterling Drug Inc. |
Sustained-release pharmaceutical tablet and process for preparation thereof
|
US4508702A
(en)
*
|
1982-06-14 |
1985-04-02 |
Key Pharmaceuticals, Inc. |
Sustained release aspirin
|
WO1984000004A1
(en)
*
|
1982-06-14 |
1984-01-05 |
Key Pharma |
Sustained release aspirin
|
DE3382392D1
(de)
*
|
1982-07-09 |
1991-10-02 |
Key Pharma |
Dosierungsart zur dauerhaften verabreichung von chinidin.
|
US4634587A
(en)
*
|
1982-07-09 |
1987-01-06 |
Key Pharmaceuticals, Inc. |
Sustained release quinidine dosage form
|
US4704284A
(en)
*
|
1982-08-12 |
1987-11-03 |
Pfizer Inc. |
Long-acting matrix tablet formulations
|
US4525339A
(en)
*
|
1982-10-15 |
1985-06-25 |
Hoffmann-La Roche Inc. |
Enteric coated oral dosage form
|
US4503031A
(en)
*
|
1982-12-17 |
1985-03-05 |
Glassman Jacob A |
Super-fast-starting-sustained release tablet
|
IE55745B1
(en)
*
|
1983-04-06 |
1991-01-02 |
Elan Corp Plc |
Sustained absorption pharmaceutical composition
|
BR8406921A
(pt)
*
|
1983-05-31 |
1985-06-04 |
Choong Gook Jang |
Composicoes secas de compressao,direta para formas de dosagem de liberacao controlada
|
US4882167A
(en)
*
|
1983-05-31 |
1989-11-21 |
Jang Choong Gook |
Dry direct compression compositions for controlled release dosage forms
|
US4555399A
(en)
*
|
1983-11-18 |
1985-11-26 |
Key Pharmaceuticals, Inc. |
Aspirin tablet
|
DE3403329A1
(de)
*
|
1984-02-01 |
1985-08-01 |
Horst Dr. 4019 Monheim Zerbe |
Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
|
US4590062A
(en)
*
|
1984-04-16 |
1986-05-20 |
Tech Trade Corp. |
Dry direct compression compositions for controlled release dosage forms
|
US4618487A
(en)
*
|
1984-07-06 |
1986-10-21 |
Alza Corporation |
Device for administering calcium ascorbate
|
US4867984A
(en)
*
|
1984-11-06 |
1989-09-19 |
Nagin K. Patel |
Drug in bead form and process for preparing same
|
EP0418596A3
(en)
*
|
1989-09-21 |
1991-10-23 |
American Cyanamid Company |
Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
|
EP0550108B1
(en)
*
|
1991-12-30 |
1998-03-18 |
Akzo Nobel N.V. |
Sustained release thyroactive composition
|
US6322819B1
(en)
*
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
US20070042041A1
(en)
*
|
2005-08-17 |
2007-02-22 |
Board Of Trustees Of The University Of Arkansas |
Drug-surfactant complexes for sustained release
|
WO2016020901A1
(en)
|
2014-08-07 |
2016-02-11 |
Acerta Pharma B.V. |
Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
|